Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome Inc.

In a report released today, Chad Messer from Lake Street maintained a Buy rating on Immunome, with a price target of $22.00. Messer covers the Heal...

Lake Street Sticks to Their Buy Rating for Immunome (IMNM)

Immunome, Inc. ( ($IMNM) ) has released its Q3 earnings. Here is a breakdown of the information Immunome, Inc. presented to its investors. Immunome...

Immunome, Inc. Reports Q3 2025 Financial Results

In a report released yesterday, from Craig-Hallum reiterated a Buy rating on Immunome. The company’s shares closed yesterday at $15.24. In addition...

Craig-Hallum Reaffirms Their Buy Rating on Immunome (IMNM)

Piper Sandler analyst Biren Amin maintained a Buy rating on Immunome today and set a price target of $21.00. The company’s shares opened today at $...

Market Cap	$1.41B	P/E Ratio	N/A
52W High	$18.94	52W Low	$5.15
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-32.7%	52W Position	97.0%
Overall Score	58	Value Score	50
Quality Score	--	Technical Score	66

EPS Current Est	$-2.33	EPS Next Est	$-2.56
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMNM	$18.53	+5.83%	1.43M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMNM	$18.53	+5.8%	1.43M
3
4
5
6

IMNM

IMNM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Immunome Inc. Data in Excel

Get Immunome Inc. Data in Excel